Sudhir Sekhsaria, MD
Allergy & Immunology · Rockville, MDNPI 1568423606
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,550 of the $86,700 with a category attached, or 82.5%. GSK accounts for 64.6% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2023 at $35,588 and has fallen 91.6% since, to $2,995 in 2025. Among allergy & immunology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 716 payments — averaging $121.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$56K
- AstraZeneca$10K
- Shire North American Group Inc$8K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$969
- plus $6K from 37 others
Across 59 payments — averaging $8395.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$294K
- Novartis$148K
- Sanofi US Services Inc.$35K
- Astrazeneca AB$14K
- Eli Lilly$4K
What the payments were for
- Speaking & faculty fees$71,55083%
- Travel & lodging$460%
- Food & beverage$14,86317%
- Education$2410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,700 in reported general payments places this provider in the 95th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 243 | $216,761 |
| Dupixent SyringeDupilumab | 37 | $134,195 |
| XolairOmalizumab | 22 | $64,411 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $24,078 |
| Spiriva RespimatTiotropium Bromide | 17 | $14,042 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,639 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 43 | $10,164 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $5,029 |
| DuleraMometasone/Formoterol | 16 | $5,010 |
| Famotidine | 271 | $4,456 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,496 |
| Azelastine Hcl | 102 | $3,491 |
| Montelukast Sodium | 161 | $2,766 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 27 | $2,639 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 99 | $2,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $55,981 | $240,839278 claims |
| Genentech, Inc.Xolair | $12 | $64,41122 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $10,429 | $16,13629 claims |
| Boehringer IngelheimSpiriva Respimat | $72 | $14,04217 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $61 | $5,02911 claims |
| MerckDulera | $16 | $5,01016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 allergy & immunology providers in Maryland.
Other allergy & immunology in Rockville
- Kristin SokolRockville$62K
- Rachel SchreiberRockville$48K
- Julia SohnRockville$16K
- Nneoma ObiejembaRockville$11K
- Paul KeiserRockville$7K
- Jordana GoldmanRockville$6K
- Gina Dapul-HidalgoRockville$5K
- Ryan BolotteRockville$4K
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.